Media headlines about TG Therapeutics (NASDAQ:TGTX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. TG Therapeutics earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.3186715614466 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

TGTX has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price objective on shares of TG Therapeutics in a research report on Monday, June 5th. ValuEngine upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Thursday, July 13th. Finally, FBR & Co restated a “buy” rating on shares of TG Therapeutics in a research report on Saturday, June 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $25.40.

TG Therapeutics (NASDAQ:TGTX) opened at 11.85 on Friday. The company has a 50-day moving average of $11.50 and a 200-day moving average of $11.35. The firm’s market capitalization is $738.37 million. TG Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. On average, equities analysts forecast that TG Therapeutics will post ($1.84) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “TG Therapeutics (TGTX) Earns News Impact Score of 0.19” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Insider Buying and Selling by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.